McDermott advises PAION on Latin America license agreement with Cristália for development and commercialization of Remimazolam

Overview


Frankfurt, May 5, 2022 – International law firm McDermott Will & Emery has advised PAION AG on a license agreement with Cristália Produtos Quimicos Farmaceuticos Ltda, Brazil. PAION grants Cristália an exclusive license for the development and commercialisation of Remimazolam in Latin America.

PAION will receive a EUR 3.5 million upfront payment and is also entitled to receive a milestone payment of EUR 1 million for an NDA (New Drug Application) submission in the territory (Latin America) and an annual payment of EUR 0.5 million for each year of market exclusivity from the launch of the product. Cristália will pay PAION 20% royalties on net sales. Cristália plan to manufacture the drug in their own plant to supply the licensed territory.

McDermott Will & Emery previously advised PAION in 2021 on the granting of exclusive licensing rights for the development and marketing of Remimazolam in Taiwan, and in 2022 on the conclusion of a distribution agreement with a distributor for the marketing of Angiotensin II, Eravacycline and Remimazolam in various CEE markets.

PAION AG was advised by Monika Emilia Richter.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts